Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Breast cancer is a heterogeneous disease with diverse molecular subtypes.
• Hormone receptor-positive (luminal) subtypes are common and often responsive to endocrine therapy.
• Endocrine resistance is a major challenge in treating these breast cancers.

Purpose of the Study:

• To review mechanisms of endocrine resistance in estrogen receptor-positive (ER+) breast cancer.
• To explore the role of intracellular signaling pathways, specifically PI3K/AKT/mTOR and cyclin-dependent kinases (CDKs), in endocrine resistance.
• To evaluate the potential of co-targeting these pathways to overcome resistance and enhance endocrine therapy efficacy.

Main Methods:

• Review of preclinical and clinical trial data.
• Focus on intracellular signaling pathways: PI3K/AKT/mTOR and CDKs.
• Analysis of cross-talk between steroid receptor signaling and other growth factor pathways.

Main Results:

• Inhibition of the PI3K/AKT/mTOR pathway shows promise in overcoming endocrine resistance.
• CDK4/6 inhibition is a viable strategy to improve endocrine treatment efficacy.
• Combined inhibition strategies may restore endocrine sensitivity in resistant breast cancer cells.

Conclusions:

• Targeting the PI3K/AKT/mTOR pathway and CDK4/6 are promising strategies for ER-positive breast cancer.
• These approaches offer potential for improved efficacy with manageable side effects.
• Further clinical trials are necessary to define optimal patient populations for dual inhibition therapies.